Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.
about
Antiplatelet and anticoagulant therapy in elective percutaneous coronary interventionMultivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patientsFrom principle to practice: bridging the gap in patient profilingWarfarin-related recurrent knee haemarthrosis treated with arterial embolisation and intra-articular injection of tranexamic acid.Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum Transfusion.Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiencyRivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.Anticoagulation after intracoronary stent insertion.Correlation between International Normalized Ratio values and sufficiency of two different local hemostatic measures in anticoagulated patients.Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
P2860
Q24793199-93529D3E-00A5-4215-B91F-262AC23DE28BQ24806783-8D695816-72F6-4F15-8A8A-C616E5C9DDB9Q27318447-C714868C-9C63-4D28-AA8C-E42BC7C9B4E5Q35823474-9E36FE38-7D0F-46F5-8B7D-CCE6FF9E711EQ35867026-E6BDD1ED-48F4-4CDB-8E51-C13FDA28EFAAQ35925359-A96F67D7-51D9-4AD2-964A-D26C76022429Q37059445-7200E653-A326-474F-98BE-34D2A6FC5F93Q37230504-5F2AFA2C-A9E7-47ED-BE83-1670C53D5042Q42578643-0E44CF17-2D8F-40D1-92E0-5CE9E726705BQ43052277-3335838B-9FF1-4E24-AF36-2E8529ECAD52Q44311743-765B46E3-67D8-4F93-96A6-03193248A277
P2860
Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Suppression of hemostatic syst ...... nts with thrombotic diatheses.
@ast
Suppression of hemostatic syst ...... nts with thrombotic diatheses.
@en
type
label
Suppression of hemostatic syst ...... nts with thrombotic diatheses.
@ast
Suppression of hemostatic syst ...... nts with thrombotic diatheses.
@en
prefLabel
Suppression of hemostatic syst ...... nts with thrombotic diatheses.
@ast
Suppression of hemostatic syst ...... nts with thrombotic diatheses.
@en
P2093
P2860
P356
P1476
Suppression of hemostatic syst ...... nts with thrombotic diatheses.
@en
P2093
E M Conway
R D Rosenberg
S Barzegar
P2860
P304
P356
10.1172/JCI113239
P407
P577
1987-12-01T00:00:00Z